AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16796730
Drug: WS 5570
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS 5570 600 mg/day and WS 5570 1200 mg/day
Trial: 19777696
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interferon-alpha (HD IFN)
Trial: 9404441
Drug: Pituitary stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pituitary stimulation tests (GnRH and TRH injections)
Trial: 24060588
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (ADM) alone or in combination with CT or IPT
Trial: 24060588
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (ADM + CT or IPT)
Trial: 20564094
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg) plus dexamethasone (40 mg)
Trial: 18501073
Drug: Continuous 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 5‐FU infusion plus oxaliplatin (n = 23)
Trial: 18501073
Drug: Weekly 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 5‐FU bolus with LV plus oxaliplatin (n = 40)
Trial: 18501073
Drug: Oxaliplatin with
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin with 2‐day infusion 5‐FU/LV (FOLFOX4, n = 41)
Trial: 8758503
Drug: Lactulose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (20 mg) taken in one intake
Trial: 8758503
Drug: Lactulose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (20 mg) taken in two intakes
Trial: 8758503
Drug: Lactulose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (20 mg) in both one and two intakes
Trial: 6110188
Drug: Dihydergot plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydergot plus (combination of dihydroergotamine and etilefrine)
Trial: 6110188
Drug: Dihydroergotamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (2 mg, 3 times daily)
Trial: 6110188
Drug: Etilefrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etilefrine (20 mg, 3 times daily)
Trial: 31047819
Drug: Combination HAL‐SJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination HAL‐SJ and occupational therapy
Trial: 25723140
Drug: Maternal ARV
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal ARV treatment
Trial: 15202047
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (group 3)
Trial: 10509038
Drug: Standard melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard melphalan and prednisone (MP) chemotherapy
Trial: 10509038
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) in poor prognosis patients with high LI (>1.2%)
Trial: 10509038
Drug: Standard melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard melphalan and prednisone (MP) chemotherapy in poor prognosis patients with high LI (>1.2%)
Trial: 10509038
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) in poor prognosis patients with high β2-M (> 3 mg/L)
Trial: 8949385
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg/day (initial treatment)
Trial: 8949385
Drug: Treatment across
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment across different geographic areas (Northern Europe vs Southern Europe)
Trial: 8949385
Drug: Treatment across
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment across different genders
Trial: 8949385
Drug: Time and
RxNorm normalized name: DayTime and NiteTime KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time and number of antihypertensive drugs
Trial: 7340880
Drug: Cimetidine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1000 mg daily)
Trial: 7340880
Drug: Cimetidine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1000 mg daily for 5 days)
Trial: 31640241
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2800 IU daily)
Trial: 26892413
Drug: Peak Vo2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak Vo2 (ml·kg(‐1)·min(‐1))
Trial: 22450017
Drug: 12.5 g
RxNorm normalized name: glycerin 12.5 GM per 20.4 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 g of lactose in 250 cc water
Trial: 22450017
Drug: 12.5 g
RxNorm normalized name: glycerin 12.5 GM per 20.4 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 g of maltose in 250 cc water
Trial: 17400977
Drug: Amiodarone (AMIO)
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiodarone (AMIO) 600 mg orally for seven days before surgery and 45 mg/hr intravenously for 48 hr postoperatively
Trial: 12015692
Drug: Ertapenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (1 g once daily)
Trial: 16048928
Drug: Piperacillin-tazobactam (3.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (3.375 g every 6 h)
Trial: 8556971
Drug: Paroxetine (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10, 20, 50 mg)
Trial: 30619887
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose carvedilol (3.125 mg twice daily) for 1 week
Trial: 19269519
Drug: Selective postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective postoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent 5-fluorouracil; n=676)
Trial: 11242378
Drug: Injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapy (anesthetics, steroids, or both)
Trial: 9644527
Drug: 7-day switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day switch therapy with parenteral cefuroxime 750 mg for 3-5 days followed by oral cefuroxime axetil 500 mg every 12 hours
Trial: 9644527
Drug: 7-day therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day therapy with parenteral cefuroxime 750 mg every 8 hours
Trial: 27838347
Drug: Fluticasone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone treatment for 6 weeks
Trial: 26268314
Drug: PanAd3‐RSV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PanAd3‐RSV vaccine
Trial: 26268314
Drug: PanAd3‐RSV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PanAd3‐RSV vaccine in combination with MVA‐RSV
Trial: 10391070
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) at a dosage of 4 mg/kg/day
Trial: 10391070
Drug: Transfer Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer Factor (TF) with one unit every third day for the first week, two units per week for the next three weeks, and one monthly unit for six months
Trial: 2050157
Drug: Metoclopramide cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide cocktail (10 mg/kg) with betamethasone (20 mg) and biperiden (5 mg)
Trial: 2050157
Drug: Dixyrazine combination
RxNorm normalized name: dixyrazine
DrugBank: Dixyrazine (DB13784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dixyrazine combination (240 mg) with betamethasone (20 mg) and biperiden (5 mg)
Trial: 2050157
Drug: Dixyrazine combination
RxNorm normalized name: dixyrazine
DrugBank: Dixyrazine (DB13784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dixyrazine combination (240 mg)
Trial: 2050157
Drug: Metoclopramide cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide cocktail (10 mg/kg)
Trial: 6617071
Drug: Codeine sulfate,
RxNorm normalized name: Codeine Sulfate, sulfate 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine sulfate, 60 mg
Trial: 6617071
Drug: Codeine sulfate,
RxNorm normalized name: Codeine Sulfate, sulfate 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine sulfate, 120 mg
Trial: 3552360
Drug: Aspirin, 650
RxNorm normalized name: Aspirin, 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 650 mg
Trial: 10711416
Drug: Fenofibrate therapy
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate therapy
Trial: 30409160
Drug: Gram stain-guided
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gram stain-guided initial antibiotic treatment
Trial: 30409160
Drug: Guidelines-based initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines-based initial antibiotic treatment
Trial: 30409160
Drug: Gram stain-guided
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gram stain-guided treatment
Trial: 30409160
Drug: Guidelines-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines-based treatment
Trial: 25324159
Drug: Early Childhood
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Childhood Oral Health Impact Scale (ECOHIS)
Trial: 22495093
Drug: Physio Acoustic
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physio Acoustic Sound (PAS) therapy, applied for 30 minutes on a mattress with an in-built PAS device during the intervention period.
Trial: 22495093
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PAS therapy), measurements continued without intervention during the wash-out period.
Trial: 21393298
Drug: Eplerenone 25-50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25-50 mg/day
Trial: 17604563
Drug: LA (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA (600 mg/day)
Trial: 11224984
Drug: New approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New approaches to treatment based on immune system recognition of genetic alterations
Trial: 7999408
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Trial: 7999408
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Trial: 7999408
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Trial: 7999408
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg fadrozole hydrochloride (CGS 169 49A) daily
Trial: 7999408
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of fadrozole hydrochloride
Trial: 28776408
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with 10 treatments of invisible infrared laser (904 nm, 3 Joules/point) over three weeks followed by an eight-week supervised strengthening exercise program
Trial: 28776408
Drug: Placebo LLLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo LLLT (identical treatment with disabled infrared laser output)
Trial: 26973326
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy with exercise (MT+Ex)
Trial: 26973326
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy with exercise without boosters (MT+Ex)
Trial: 26973326
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy with exercise with boosters (MT+Ex+B)
Trial: 20116457
Drug: Enhanced Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Medical Management (EMM; SMM plus individual drug counseling)
Trial: 16186674
Drug: Oral butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral butorphanol 0.2 mg/kg
Trial: 19546692
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg/kg
Trial: 10663451
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg as single oral dose at 2200 hours)
Trial: 8880941
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg nicotine
Trial: 8880941
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg nicotine
Trial: 6486761
Drug: Ribavirin aerosol
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin aerosol treatment
Trial: 31040088
Drug: Mannitol, 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol, 0.25 g/kg/h
Trial: 24999797
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 8 weeks
Trial: 22250032
Drug: IVIG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG treatment after day 10
Trial: 22250032
Drug: IVIG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG treatment before day 10 (control)
Trial: 16890688
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg daily)
Trial: 15709841
Drug: Behavioral couple
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral couple therapy for infidelity couples
Trial: 10814600
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg)
Trial: 8566638
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine 0.02 mg/kg (maximum 0.4 mg)
Trial: 8566638
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine with meperidine
Trial: 19552750
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care from a clinical pharmacist
Trial: 22683276
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical clonidine gel applied 3 times a day for 12 weeks
Trial: 20404228
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive fractional radiofrequency (FRF) treatment
Trial: 11599643
Drug: Fluoxetine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine maintenance treatment during a 62-week study
Trial: 22695403
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (CONTROL)
Trial: 17409767
Drug: High dialysate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dialysate calcium (HdCa) concentration of 1.75 mmol/l
Trial: 17409767
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate calcium (LdCa) concentration of 1.25 mmol/l
Trial: 11779668
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg or 2 mg of oral naloxone, three times daily
Trial: 9690726
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 3 mg/60 mL enema (BDP)
Trial: 9690726
Drug: Prednisolone sodium
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone sodium phosphate 30 mg/60 mL enema (PP)
Trial: 7916398
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Enteral feeding and Total parenteral nutrition)
Trial: 29938557
Drug: Schema-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema-focused cognitive group therapy (11 sessions)
Trial: 29938557
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control group (no immediate treatment)
Trial: 23704912
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant therapy
Trial: 10702883
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg cilostazol suspension
Trial: 10702883
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg cilostazol tablet
Trial: 10702883
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg cilostazol ethanolic solution
Trial: 10702883
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat meal with 100 mg cilostazol
Trial: 16629348
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 to 40 mg daily)
Trial: 8726790
Drug: Maprotiline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (50 to 150 mg daily)
Trial: 7067470
Drug: Stepped Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped Care (SC) treatment with extensive efforts to reduce barriers to care
Trial: 7067470
Drug: Educational level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational level as a predictor of drug adherence
Trial: 30314417
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral treatment
Trial: 26544859
Drug: Virtual walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Virtual walking treatment
Trial: 24569459
Drug: KRN23 (0.003-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRN23 (0.003-0.3 mg/kg i.v. or 0.1-1 mg/kg s.c.)
Trial: 19046855
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 2.5 mg
Trial: 19046855
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 5.0 mg
Trial: 19046855
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 2.5 mg
Trial: 19046855
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (both doses)
Trial: 14720531
Drug: Amiodarone 400mg
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiodarone 400mg BD for 2 weeks prior to DCCV and 200mg daily for 8 weeks followed by placebo for 44 weeks
Trial: 14720531
Drug: Amiodarone 400mg
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiodarone 400mg BD for 2 weeks then 200mg daily for 52 weeks
Trial: 28242632
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m2 intravenously on days 1 and 8
Trial: 28242632
Drug: Dacarbazine 850,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine 850, 1,000, or 1,200 mg/m2 intravenously on day 1 of a 21-day cycle
Trial: 19186315
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg (adjustable to 25 mg or 100 mg based on patient response)
Trial: 16760504
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (500-1,500 microg/day) plus oral iron
Trial: 15526012
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron alone
Trial: 14985229
Drug: Fat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat (50 g/m² body surface)
Trial: 14985229
Drug: Glucose (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (37.5 g/m²)
Trial: 8499958
Drug: Systen (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systen (3.2 mg micronized 17 beta-estradiol transdermal patch)
Trial: 8499958
Drug: Estraderm (older
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estraderm (older transdermal therapeutic system)
Trial: 23458232
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (Control)
Trial: 25248648
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine (8 ml h(‐1))
Trial: 25248648
Drug: 0.4% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% ropivacaine (2 ml h(‐1))